Europe Genome Editing Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Technology (CRISPR, TALEN, Antisense, and Other), Application (Cell Line Engineering, Genetic Engineering, Diagnostic Applications, Drug Discovery, and Others), and E

Europe Genome Editing Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Technology (CRISPR, TALEN, Antisense, and Other), Application (Cell Line Engineering, Genetic Engineering, Diagnostic Applications, Drug Discovery, and Others), and End User (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, and Clinical Research Organizations)

The genome editing market in Europe is expected to grow from US$ 1,487.30 million in 2021 to US$ 4,791.46 million by 2028; it is estimated to grow at a CAGR of 18.2% from 2021 to 2028. According to the World Health Organization (WHO), cancer is the biggest cause of death in the region. Overall, the burden of cancer incidence and death is quickly increasing, reflecting both population aging and growth, as well as changes in the prevalence and distribution of the key cancer risk factors, many of which are related to socio-economic development. CANCER TODAY enabled a comprehensive assessment of the cancer burden. According to recent estimates, the incidence of cancer has been increasing at an alarming rate, making hepatocellular carcinoma (HCC the fifth most common cancer in men and the seventh most common cancer in women. HCC is likely to contribute to 5.6% of all human cancers, thereby increasing the burden in 2020. The HCC is known to be the second leading cause of cancer-related deaths worldwide and almost 85% of HCCs occur in developing countries. Other types of liver cancers are cholangiocellular carcinoma (CCC), a malignant disease of the liver bile ducts, and hepatoblastoma. Hepatoblastoma is the most common malignant tumor of the liver in children. Thus, a rise in the prevalence of liver diseases, including chronic and acute diseases and microbial infections, increases the demand for liver models. A chromosomal abnormality can be detected in about one out of every 150 live births. Yet even this high incidence represents only a small fraction of chromosome mutations since the vast majority are lethal and result in prenatal death or stillbirth. Indeed, 50% of all first-trimester miscarriages and 20% of all second-trimester miscarriages are estimated to involve a chromosomally abnormal fetus. Although Down syndrome is the most well-known and well-recognized autosomal trisomies, it is only diagnosed in around one out of every 800 live births. Many cancer biology investigations are now using CRISPR as a standard approach. The CRISPR/Cas9 system has been shown to be effective in treating metastatic tumors, which is a big step toward discovering a cancer cure. The CRISPR-LNPs system contains a messenger RNA that encodes for the Cas9 CRISPR enzyme, which operates as molecular scissors to cut the DNA of cells. CRISPR-based studies have opened new doors to treating hereditary or developmental neurological disorders (HNDs) such as fragile X syndrome and Down syndrome. Thus, the increasing factors of genome editing are expected to boost the growth of the genome editing market during the forecast period.

Countries in the European regions were profoundly affected due to the COVID-19 pandemic. For instance, countries such as Italy, Spain, and France have reported the highest number of positive cases and have registered the maximum number of deaths. The cell therapy instruments supply chain, which is already logistically complicated, faced new challenges. The cell therapy instrument market witnessed some shortfall at the beginning of the COVID-19 crisis due to factors such as disruption in the supply chain and due to lockdown announced by the majority of European countries. For instance, in July 2020, the UK government allotted 100 million Euros funds to the Cell and Gene Therapy Catapult Manufacturing Innovation Centre to expedite the production of a vaccine for COVID-19 in the UK. Moreover, Stempeutics Research has filed an application seeking European Commission Funding to develop cell therapy for COVID-19. The company has also entered into a partnership with a global consortium of cell therapy companies to gather funding for cell therapy research from the European Commission. Hence, the Europe genome editing market is likely to show significant growth prospects during this pandemic and forecasted year.

The Europe genome editing market is segmented into technology, application, and end user. Based on application, the market is segmented into cell line engineering, genetic engineering, diagnostic applications, drug discovery, and others. In 2021, genetic engineering segment held the largest share in the market. Cell line engineering is majorly done in laboratories, and it is performed to understand the basic biology behind the diseases and therapeutics. Cell line engineering provides benefits such as optimizing cell lines for the recombinant protein expression and characterization of the protein profile of genetically modified organisms. Cell line engineering enables the production of various industrial and commercial products that gain much more revenue as the products are produced per the desired requirement. Market players such as Horizon Discovery, Thermo Fisher Scientific, Lonza, Merck KGaA and Biognosys provide the products and services for cell line engineering. There are various advantages of the cell line engineering, such as cost-effective, easy to use, providing an unlimited supply of material, and bypassing ethical concerns associated with the use of animal and human tissues. In addition, cell line engineering has benefitted researchers for developing a vaccine, testing drug metabolism and cytotoxicity, antibody production, the study of gene function, generation of artificial tissues, and synthesis of biological compounds. Thus, the factors mentioned above are driving the growth of the genetic engineering segment in the market.

The overall Europe genome editing market size has been derived using both primary and secondary sources. To begin the research process, exhaustive secondary research has been conducted using internal and external sources to obtain qualitative and quantitative information related to the market. The process also serves the purpose of obtaining overview and forecast for the Europe genome editing market with respect to all the market segments. Also, multiple primary interviews have been conducted with industry participants to validate the data and to gain more analytical insights into the topic. The participants typically involved in this process include industry experts such as VPs, business development managers, market intelligence managers, and national sales managers—along with external consultants such as valuation experts, research analysts, and key opinion leaders—specializing in the Europe genome editing market. THERMO FISHER SCIENTIFIC INC. ,MERCK KGaA, Lonza, Horizon Discovery Group plc., Integrated DNA Technologies, GenScript, New England Biolabs, Eurofins Scientific, and CRISPR Therapeutics are among the leading companies in the market.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Europe genome editing market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the Europe genome editing market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the genome editing market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution